Deals In Depth: November 2017
Executive Summary
Bayer got rights to potentially tissue-agnostic therapies from Loxo in a $1.6 billion deal; Cardinal Health sold its Chinese distribution business to Shanghai Pharmaceuticals for $1.2 billion. Biopharma financing totaled nearly $5 billion, fueled mostly by follow-on and debt offerings.